India Moves to Tighten Microbial Contamination Standards in Sterile Drug Manufacturing

The Union Ministry of Health and Family Welfare has proposed changes to Schedule M of the Drugs Rules, 1945, aimed at strengthening microbial contamination controls in sterile pharmaceutical manufacturing facilities. The proposed revisions seek to bring India's Good Manufacturing Practices (GMP) requirements closer to standards established by the World Health Organization (WHO).

The draft amendment, issued through Gazette Notification G.S.R. 953(E) dated 28 October 2026, focuses on microbial monitoring requirements in Grade A clean areas. These highly controlled environments are used during critical manufacturing operations, particularly when sterile medicines, exposed containers and sterilised components are handled.

Under the existing Schedule M provisions, the recommended microbial contamination limit for Grade A areas is less than one colony-forming unit (CFU). The proposed amendment seeks to align this requirement with WHO Technical Report Series No. 1044, Annex 2, which specifies that any microbial growth detected in these critical areas should prompt an investigation.

The proposed changes are intended to address differences between Indian regulations and internationally recognised GMP standards. Greater consistency in microbial monitoring requirements is expected to support contamination control and strengthen quality assurance practices in sterile pharmaceutical production.

The Ministry has also invited comments, objections and suggestions from industry stakeholders and the public before finalising the amendment. This consultation will allow relevant parties to review the proposed regulatory changes and submit their observations.

If implemented, the revised provisions would further reinforce India's regulatory framework for sterile drug manufacturing, with increased emphasis on microbial control, product quality and patient safety.

04-11-2026